ResearcherWashington University in St. LouisNo recent work listed
Jennifer N. Uram
Matched on OpenAlex author ID A5058389360. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2013: 3 papers · 2014: none · 2015: 1 paper
Papers 4
- Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗
- Current advances in immunotherapy for pancreatic cancer. Co-author DOI 10.1016/j.currproblcancer.2013.10.004↗
- Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Co-author DOI 10.1097/cji.0b013e31829fb7a2↗
- Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor v… Co-author DOI 10.1245/s10434-013-3262-5↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dung Thi Le · 3 shared papers, 2013–2015 · strength 0.15
- Paper Current advances in immunotherapy for pancreatic cancer. DOI 10.1016/j.currproblcancer.2013.10.004↗
- Paper Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines … DOI 10.1200/jco.2014.57.4244↗
- Paper Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previo… DOI 10.1097/cji.0b013e31829fb7a2↗
- Elizabeth M. Jaffee · 3 shared papers, 2013–2015 · strength 0.11
- Paper Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines … DOI 10.1200/jco.2014.57.4244↗
- Paper Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receivi… DOI 10.1245/s10434-013-3262-5↗
- Paper Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previo… DOI 10.1097/cji.0b013e31829fb7a2↗
- Daniel A. Laheru · 3 shared papers, 2013–2015 · strength 0.11
- Paper Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines … DOI 10.1200/jco.2014.57.4244↗
- Paper Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receivi… DOI 10.1245/s10434-013-3262-5↗
- Paper Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previo… DOI 10.1097/cji.0b013e31829fb7a2↗
- Eric R. Lutz · 2 shared papers, 2013–2015 · strength 0.07
- Paper Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines … DOI 10.1200/jco.2014.57.4244↗
- Paper Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previo… DOI 10.1097/cji.0b013e31829fb7a2↗
- Deirdre Jill Cohen · 1 shared paper, 2015 · strength 0.04
- Gregory M. Springett · 1 shared paper, 2015 · strength 0.04
- Todd S. Crocenzi · 1 shared paper, 2015 · strength 0.04
- Dirk G. Brockstedt · 1 shared paper, 2015 · strength 0.04
- Tim F. Greten · 1 shared paper, 2015 · strength 0.04
- Herbert J. Zeh · 1 shared paper, 2015 · strength 0.04
- Michael Andrew Morse · 1 shared paper, 2015 · strength 0.04
- Robert Lance Fine · 1 shared paper, 2015 · strength 0.04
- Andrea Wang‐Gillam · 1 shared paper, 2015 · strength 0.04
- Vincent J. Picozzi · 1 shared paper, 2015 · strength 0.04
- Aaron J. Schueneman · 1 shared paper, 2013 · strength 0.04
- Elaine O. Bigelow · 1 shared paper, 2013 · strength 0.04
- Joseph M. Herman · 1 shared paper, 2013 · strength 0.04
- Barish H. Edil · 1 shared paper, 2013 · strength 0.04
- Lei Zheng · 1 shared paper, 2013 · strength 0.04
- Lei Zheng · 1 shared paper, 2013 · strength 0.03
- Ross C. Donehower · 1 shared paper, 2013 · strength 0.03
- Luis Alberto Diaz · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.